News

The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting two inflammatory mediators, proteins which play a key role in major autoimmune diseases. "This is

Qudexy XR and Topiramate Extended-Release Capsules are indicated as initial monotherapy in patients 10 years of age and older with partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

The study is designed to assess the safety and anti-pruritic efficacy of Nalbuphine ER tablets in about 360 hemodialysis patients to be enrolled in the US and Europe.

As part of the deal, GSK secured a license to use Codexis’ proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. The license enables the

As part of the deal, Abbott will carve out the assets and transfer them to a new public company, New Mylan, organised in the Netherlands. After transfer of

According to the company, Rasuvo will be available in ten dosage strengths, ranging from 7.5mg to 30mg in 2.5mg increments and will be launched in the US. The

The Phase III trial met its primary endpoint and showed that the combination therapy helped these patients live significantly longer without their disease worsening (progression-free survival; PFS) compared

The study is on track with Genticel’s initial projections. All of the 39 investigation sites across seven European countries (Belgium, Finland, France, Germany, the Netherlands, Spain and the

The results show overall efficacy against symptomatic dengue of 56.5% in children aged two to 14 years old after a three-dose vaccination schedule. A total of 10,275 children